(Q38052844)

27 August 2017

The hepatitis C virus infection as a systemic disease (English)

1 reference

27 August 2017

1 reference

1 reference

1

Anna Linda Zignego

1 reference

27 August 2017

Laura Gragnani

2

1 reference

PubMed ID

23073858

27 August 2017

Carlo Giannini

series ordinal

3

1 reference

PubMed ID

23073858

27 August 2017

Giacomo Laffi

series ordinal

4

1 reference

27 August 2017

1 October 2012

1 reference

Internal and emergency medicine

27 August 2017

1 reference

27 August 2017

7 Suppl 3

1 reference

27 August 2017

S201-8

1 reference

https://scigraph.springernature.com/pub.10.1007/s11739-012-0825-6

27 August 2017

0 references

cites work

Infection of peripheral mononuclear blood cells by hepatitis C virus

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus lymphotropism: lessons from a decade of studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Extrahepatic manifestations of HCV infection: facts and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma: evidence for a pathogenetic role

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus infection in patients with essential mixed cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Clonal B cell populations in the blood and liver of patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus (HCV) infection: a systemic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Cryoglobulinemia--a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Neurologic complications associated with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus-related lymphoproliferative disorders: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Cryoglobulinemia with vasculitis associated with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Preliminary classification criteria for the cryoglobulinaemic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Association between mixed cryoglobulinemia, translocation (14;18), and persistence of occult HCV lymphoid infection after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Association between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Efficacy and safety of rituximab in type II mixed cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Non-Hodgkin's lymphoma: possible role of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus infection in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Binding of hepatitis C virus to CD81

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Immunoglobulin mimicry by Hepatitis C Virus envelope protein E2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus RNA in the bone marrow of patients with mixed cryoglobulinemia and in subjects with noncryoglobulinemic chronic hepatitis type C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus-related lymphomagenesis in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Involvement of PI3K in HCV-related lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

T(14;18) translocation in chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Random aneuploidy in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Involvement of chemokines and type 1 cytokines in the pathogenesis of hepatitis C virus-associated mixed cryoglobulinemia vasculitis neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Elevated Serum Levels of Osteopontin in HCV-Associated Lymphoproliferative Disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune response, or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcγ receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Membranoproliferative glomerulonephritis associated with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Renal manifestations of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

The magnitude of the association between hepatitis C virus infection and oral lichen planus: meta-analysis and case control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Hepatitis C virus RNA localization in human carotid plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Atherosclerosis risk in HIV-infected patients: the influence of hepatitis C virus co-infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Usefulness of anti-CCP antibodies in patients with hepatitis C virus infection with or without arthritis, rheumatoid factor, or cryoglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

The liver-cytokine-brain circuit in interferon-based treatment of patients with chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

HCV patients, psychopathology and tryptophan metabolism: analysis of the effects of pegylated interferon plus ribavirin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11739-012-0825-6

Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia

21 January 2018

1 reference

12 December 2020

Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia

1 reference

12 December 2020

Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between primary Sjögren's syndrome and hepatitis C in Swedish patients

1 reference

12 December 2020

Effects of long-term course of alpha-interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia

1 reference

12 December 2020

Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial

1 reference

12 December 2020

Thyroid cancer in patients with hepatitis C infection

1 reference

12 December 2020

Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders.

1 reference

12 December 2020

Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis

1 reference

12 December 2020

Cryoglobulinaemia related to Sjogren's syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy

1 reference

12 December 2020

Performance of the preliminary classification criteria for cryoglobulinaemic vasculitis and clinical manifestations in hepatitis C virus-unrelated cryoglobulinaemic vasculitis.

1 reference

12 December 2020

Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia

1 reference

12 December 2020

Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection.

1 reference

12 December 2020

Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients

1 reference

12 December 2020

Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study

1 reference

12 December 2020

Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage.

1 reference

12 December 2020

Frequency of bcl-2 rearrangement in patients with mixed cryoglobulinemia and HCV-positive liver diseases

1 reference

12 December 2020

Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia?

1 reference

12 December 2020

Detailed analysis of the E2-IgM complex in hepatitis C-related type II mixed cryoglobulinaemia

1 reference

12 December 2020

Thyroid cancer in HCV-related mixed cryoglobulinemia patients

1 reference

12 December 2020

10.1007/S11739-012-0825-6

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

23073858